These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 20478852)

  • 21. Clozapine and fluvoxamine, a curious complexity.
    Shader RI; Greenblatt DJ
    J Clin Psychopharmacol; 1998 Apr; 18(2):101-2. PubMed ID: 9555594
    [No Abstract]   [Full Text] [Related]  

  • 22. Potential drug interactions with melatonin.
    Papagiannidou E; Skene DJ; Ioannides C
    Physiol Behav; 2014 May; 131():17-24. PubMed ID: 24732412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosynthesis of Fluorinated Analogs of Drugs Using Human Cytochrome P450 Enzymes Followed by Deoxyfluorination and Quantitative Nuclear Magnetic Resonance Spectroscopy to Improve Metabolic Stability.
    Obach RS; Walker GS; Brodney MA
    Drug Metab Dispos; 2016 May; 44(5):634-46. PubMed ID: 26921388
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluvoxamine-theophylline interaction: gap between in vitro and in vivo inhibition constants toward cytochrome P4501A2.
    Yao C; Kunze KL; Kharasch ED; Wang Y; Trager WF; Ragueneau I; Levy RH
    Clin Pharmacol Ther; 2001 Nov; 70(5):415-24. PubMed ID: 11719727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism and
    Yu C
    Xenobiotica; 2020 Nov; 50(11):1285-1300. PubMed ID: 32394778
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of three-compartment physiologically based pharmacokinetic modeling to predict hepatic blood levels of fluvoxamine relevant for drug-drug interactions.
    Iga K
    J Pharm Sci; 2015 Apr; 104(4):1478-91. PubMed ID: 25558834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo.
    Becquemont L; Le Bot MA; Riche C; Beaune P
    Fundam Clin Pharmacol; 1996; 10(2):156-7. PubMed ID: 8737959
    [No Abstract]   [Full Text] [Related]  

  • 28. Early Administration of Ramelteon in the ICU: Effects Deserve Further Study.
    Jiang S; Shen Y; Zhao X
    Crit Care Med; 2018 Oct; 46(10):e1010. PubMed ID: 30216315
    [No Abstract]   [Full Text] [Related]  

  • 29. Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice.
    Khafaji AWM; Al-Zubaidy AAK; Farhood IG; Salman HR
    Naunyn Schmiedebergs Arch Pharmacol; 2024 Mar; ():. PubMed ID: 38446218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melatonin and melatonergic drugs in sleep disorders.
    Kim HK; Yang KI
    Transl Clin Pharmacol; 2022 Dec; 30(4):163-171. PubMed ID: 36632077
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, Safety, and Drug-Drug Interactions for Insomnia Therapy in COVID-19 Patients.
    Saputra BD; Levita J; Mustarichie R
    J Multidiscip Healthc; 2022; 15():137-152. PubMed ID: 35087274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance.
    Ring B; Wrighton SA; Mohutsky M
    Methods Mol Biol; 2021; 2342():29-50. PubMed ID: 34272690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-drug and drug-drug interaction in COVID-19: Risk and assessment.
    Kumar D; Trivedi N
    Biomed Pharmacother; 2021 Jul; 139():111642. PubMed ID: 33940506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug-Drug Interactions Involving Intestinal and Hepatic CYP1A Enzymes.
    Klomp F; Wenzel C; Drozdzik M; Oswald S
    Pharmaceutics; 2020 Dec; 12(12):. PubMed ID: 33322313
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Defining the Contribution of CYP1A1 and CYP1A2 to Drug Metabolism Using Humanized CYP1A1/1A2 and Cyp1a1/Cyp1a2 Knockout Mice.
    Kapelyukh Y; Henderson CJ; Scheer N; Rode A; Wolf CR
    Drug Metab Dispos; 2019 Aug; 47(8):907-918. PubMed ID: 31147315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic Drug Interactions with Tobacco, Cannabinoids and Smoking Cessation Products.
    Anderson GD; Chan LN
    Clin Pharmacokinet; 2016 Nov; 55(11):1353-1368. PubMed ID: 27106177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers.
    Gabriel L; Tod M; Goutelle S
    Clin Pharmacokinet; 2016 Aug; 55(8):977-90. PubMed ID: 26936044
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Artificial neural network cascade identifies multi-P450 inhibitors in natural compounds.
    Li Z; Li Y; Sun L; Tang Y; Liu L; Zhu W
    PeerJ; 2015; 3():e1524. PubMed ID: 26719820
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sulfation of 6-hydroxymelatonin, N-acetylserotonin and 4-hydroxyramelteon by the human cytosolic sulfotransferases (SULTs).
    Luo L; Zhou C; Kurogi K; Sakakibara Y; Suiko M; Liu MC
    Xenobiotica; 2016 Jul; 46(7):612-619. PubMed ID: 26577053
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.